The management of metabolic disorders, particularly those related to uric acid levels, has seen significant advancements with the development of targeted therapeutic agents. Verinurad, identified by its CAS number 1352792-74-5, stands out as a crucial compound in this domain due to its potent inhibitory effect on the Urate Transporter 1 (URAT1).

URAT1 is a protein located in the kidneys that plays a pivotal role in the reabsorption of uric acid. By inhibiting URAT1, Verinurad effectively reduces the kidneys' ability to retain uric acid, leading to increased urinary excretion and subsequently lowering the concentration of uric acid in the blood. This mechanism makes it a highly effective agent for treating conditions characterized by high uric acid levels, such as gout and hyperuricemia. The scientific community often refers to Verinurad by its developmental code, RDEA3170.

The pharmaceutical industry relies on compounds like Verinurad as key research tools and potential drug candidates. Its consistent purity and well-defined chemical properties make it an invaluable pharmaceutical intermediate for further synthesis and formulation studies. Researchers investigate its efficacy in preclinical models and clinical trials to establish its safety and therapeutic benefit in patients. The focus on Verinurad for gout treatment stems from the direct link between elevated uric acid and the manifestation of gout symptoms.

The ongoing research into RDEA3170 drug development aims to optimize its delivery and efficacy, exploring its potential in monotherapy and combination treatments. As one of the leading hyperuricemia treatment options, Verinurad represents a significant stride in precision medicine, targeting specific molecular pathways responsible for the disease. The availability of high-quality Verinurad is essential for these research endeavors.

In summary, Verinurad (CAS 1352792-74-5) is more than just a chemical compound; it is a critical component in the ongoing effort to combat metabolic disorders. Its role as a URAT1 inhibitor and a selective uric acid reabsorption inhibitor positions it as a vital tool in pharmaceutical research and a promising therapeutic agent for conditions like gout, underscoring the importance of continued investigation into its full potential.